Actively Recruiting
The Effect of Erythropoietin on Alveolar Fluid Clearance in Patients With Acute Respiratory Distress Syndrome
Led by Second Affiliated Hospital of Wenzhou Medical University · Updated on 2023-05-15
40
Participants Needed
1
Research Sites
201 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Acute respiratory distress syndrome (ARDS) is a common acute and critical disease in clinic. The clinical mortality is as high as 30%-40%. At present, there is no specific treatment. Erythropoietin (EPO), also known as erythrocyte- stimulating factor, erythropoietin, has a certain amount in normal human body, mainly synthesized by liver in infants and kidneys in adults, which can stimulate erythropoiesis. In recent years, more and more studies have shown that high-dose exogenous EPO administration has benefit effects on multi-organ protection. Therefore, we designed this prospective, double-blind, placebo-controlled trial for defecting EPO on the alveolar fluid clearance of ARDS. The study mainly answers the following questions: Does human erythropoietin accelerate the resolution of alveolar edema in ARDS? Is there any effect on hospital survival? The study will draw conclusions by comparing the control group with the experimental group.
CONDITIONS
Official Title
The Effect of Erythropoietin on Alveolar Fluid Clearance in Patients With Acute Respiratory Distress Syndrome
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age ≥18 years
- Diagnosed with sepsis 3.0
- Undergoing tracheal intubation and mechanical ventilation
- Diagnosed with ARDS according to Berlin criteria
- Willing to accept treatment and sign informed consent form
You will not qualify if you...
- Age <18 years
- Pregnant or breastfeeding women
- Patients with malignant tumors
- Allergy to recombinant human erythropoietin (rhEPO)
- Hemoglobin level ≥120 g/L
- Recent use of rhEPO (within 3 months) or participation in other clinical trials
- History of thromboembolic diseases such as pulmonary embolism, heart attack, cerebral infarction, or thrombosis
- Unable or unwilling to provide informed consent or follow study requirements
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
SAHWenzhouMU
Wenzhou, Zhejiang, China, 325000
Actively Recruiting
Research Team
S
Shengwei Jin, Professor
CONTACT
Y
Yuqiang Gong, Professor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here